Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
Recent studies show that FDA-approved antiretroviral FTC/TAF may slow aging by reducing retrotransposon activity, highlighting a promising gerotherapeutic approach with broad accessibility. Groundbrea...
Muscle-generated exerkines in extracellular vesicles are crucial for exercise-induced health, with new research suggesting therapies for sarcopenia and metabolic diseases through inter-organ communica...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Emerging research shows that enhancing mRNA surveillance mechanisms like nonsense-mediated decay can reduce neurodegeneration, with innovative therapies targeting tau aggregation offering new hope. Re...
Recent studies on hydra’s negligible senescence overturn traditional aging models, suggesting aging is adaptable and offering clues for anti-aging biotech interventions. New research reveals hyd...
Recent research shows lipid nanoparticles delivering mRNA can reduce tau protein aggregates in Alzheimer’s models, with Moderna advancing clinical trials and regulatory support accelerating deve...
Recent ethical debates in longevity science highlight public support for life extension with equity, expert calls for transparency, and policy integration to address ageism and access disparities. Adv...
Partial OSK reprogramming rejuvenates engram neurons in aged mice, improving memory by over 50%, with recent studies enhancing safety and biotech firms advancing towards human trials. New research sho...
Advancements in genetic testing and AI are enabling highly tailored nutrition recommendations, moving beyond generic guidelines to optimize health based on individual biological profiles. The fusion o...
